Organs-on-Chips

Organs-on-Chips

Global Organs-on-Chips Market to Reach US$558.5 Billion by 2030

The global market for Organs-on-Chips estimated at US$67.2 Billion in the year 2023, is expected to reach US$558.5 Billion by 2030, growing at a CAGR of 35.3% over the analysis period 2023-2030. Liver-on-Chip, one of the segments analyzed in the report, is expected to record a 36.6% CAGR and reach US$206.0 Billion by the end of the analysis period. Growth in the Kidney-on-Chip segment is estimated at 37.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$18.8 Billion While China is Forecast to Grow at 33.4% CAGR

The Organs-on-Chips market in the U.S. is estimated at US$18.8 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$79.9 Billion by the year 2030 trailing a CAGR of 33.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 31.8% and 29.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 24.3% CAGR.

Global Organs-on-Chips Market – Key Trends & Drivers Summarized

What Are Organs-on-Chips, and Why Are They Revolutionizing Biomedical Research?

Organs-on-chips are micro-engineered devices that mimic the functions and structures of human organs by combining living cells with advanced microfluidic systems. These devices are typically made from flexible, translucent materials that allow for real-time monitoring and analysis of cellular behavior, enabling researchers to study organ function and disease processes in a highly controlled environment. By simulating the physiological conditions of specific organs—such as the lung, liver, kidney, or heart—organs-on-chips offer a powerful alternative to traditional animal testing and cell cultures. The potential applications for organs-on-chips extend across drug discovery, disease modeling, and personalized medicine. Pharmaceutical companies and research institutions are using these devices to test drug efficacy and toxicity more accurately, reducing the reliance on animal models and increasing the precision of human-based studies. As personalized medicine gains prominence, the ability of organs-on-chips to model individual patient responses further highlights their potential to transform the field of biomedical research.

How Are Technological Innovations Advancing the Organs-on-Chips Industry?

The organs-on-chips market is experiencing rapid growth due to innovations in materials science, microfluidics, and tissue engineering. Advances in 3D bioprinting and microfabrication technologies have significantly enhanced the design and functionality of organs-on-chips, enabling the creation of more complex, multi-tissue models that can replicate not just individual organ functions, but also the interactions between different organs. These technological strides allow for the creation of interconnected organ systems, also known as "body-on-a-chip" models, which better simulate the systemic effects of drugs and diseases in the human body. Further, developments in sensor technologies and imaging techniques are improving the ability to monitor cellular responses in real time, providing detailed insights into how drugs or disease processes affect human tissue at the cellular level. Researchers are also exploring the integration of artificial intelligence (AI) and machine learning algorithms to analyze data generated from organs-on-chips, enhancing predictive models for drug toxicity and therapeutic outcomes. These advances are accelerating the adoption of organs-on-chips in both academic research and industrial settings.

Where Are Organs-on-Chips Being Used Most Prominently?

Organs-on-chips are being used extensively in the pharmaceutical industry, academic research, and personalized medicine. Pharmaceutical companies are increasingly relying on these devices for drug discovery and preclinical testing, as they offer a more reliable and cost-effective way to evaluate drug safety and efficacy than traditional methods. The ability of organs-on-chips to replicate human organ responses with high fidelity makes them ideal for screening potential drug candidates and identifying toxic effects early in the development process. In academic and biomedical research, organs-on-chips are being employed to model a wide range of diseases, including cancer, cardiovascular conditions, and neurological disorders. These models allow researchers to investigate disease mechanisms and test new treatments in a human-relevant context. In personalized medicine, organs-on-chips are being explored as a tool for developing patient-specific therapies, where cells from individual patients can be used to create custom organ models that predict how they will respond to treatments. This is especially valuable for conditions such as cancer, where treatment responses can vary significantly between patients.

What Is Driving the Growth of the Organs-on-Chips Market?

The growth in the organs-on-chips market is driven by several factors, including the increasing demand for alternatives to animal testing, the rise of personalized medicine, and technological advancements in microfluidics and tissue engineering. One of the key drivers is the growing recognition that traditional animal models often fail to accurately predict human responses to drugs and diseases, creating a demand for more reliable, human-based testing platforms. Regulatory pressure to reduce animal testing, along with ethical concerns, has further fueled interest in organs-on-chips as a more humane and scientifically robust alternative. Additionally, the rise of personalized medicine, where treatments are tailored to individual patients, is driving demand for customized organ models that can predict patient-specific drug responses. Advances in microfabrication and tissue engineering are also expanding the capabilities of organs-on-chips, making them more versatile and accessible for a broader range of applications. Finally, increasing investment in biomedical research, coupled with collaborations between academic institutions, pharmaceutical companies, and government agencies, is accelerating the adoption and commercialization of organs-on-chips across the globe.

Select Competitors (Total 12 Featured) -

• Ascendance Biotechnology, Inc.
• AxoSim, Inc.
• CN Bio Innovations Ltd.
• Emulate, Inc.
• Hurel Corporation
• InSphero AG
• Kirkstall Ltd.
• Mimetas
• Nortis, Inc.
• SynVivo
• TissUse GmbH

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.